Oxaliplatin, a platinum-containing antineoplastic agent, is a key drug for the treatment of colorectal cancer and gastric cancer; however, some patients develop allergic reactions. Our hospital uses a regimen to control allergic reactions in patients with mild allergies(Grade 1 and 2). The aim of this study was to determine the effectiveness and safety of our allergy regimen. We retrospectively investigated 22 patients who initiated our allergy regimen between January 2017 and December 2017. The median number of administration cycles before allergy development was 8, and the median cumulative dose of oxaliplatin was 700mg/m2. Of the 22 patients, 18(82%)were able to continue oxaliplatin therapy. Drowsiness was the only adverse event that occurred in this cohort. Our allergy regimen may be effective for controlling allergic reactions to oxaliplatin in patients with mild allergies.